"Following the 2014 Ebola outbreak in West Africa that took the lives of more than 11,200 people in the region, the National Eye Institute, part of the National Institutes of Health, has deployed a team of clinicians and technical experts to Monro"...
The Vitrasert (ganciclovir) Implant is not a cure for CMV retinitis, and some immunocompromised patients may continue to experience progression of retinitis with the Vitrasert (ganciclovir) Implant. Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of the Vitrasert (ganciclovir) Implant.
As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place the Vitrasert (ganciclovir) Implant into the vitreous cavity may include, but are not limited to, the following: intraocular infection or inflammation, detachment of the retina, and formation of cataract in the natural crystalline lens.
Following implantation of the Vitrasert (ganciclovir) Implant, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately two to four weeks post-operatively. This decrease in visual acuity is likely a result of the surgical implant procedure.
The Vitrasert (ganciclovir) Implant only treats eyes in which it has been implanted. Additionally, because CMV is a systemic disease, patients should be monitored for extraocular CMV infections (e.g., pneumonitis, colitis) in the body.
Patients should be advised that ganciclovir has caused decreased sperm production in animals and may cause infertility in humans. Women of childbearing potential should be advised that ganciclovir causes birth defects in animals and should not be used during pregnancy.
Patients should be advised that ganciclovir has caused tumors in animals. Although there is no information from human studies, ganciclovir should be considered a potential carcinogen.
Last reviewed on RxList: 12/2/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Vitrasert Information
- Vitrasert Drug Interactions Center: ganciclovir io
- Vitrasert Side Effects Center
- Vitrasert Overview including Precautions
- Vitrasert FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.